...
search icon
aldx-img

Aldeyra The, Common Stock

ALDX

NAQ

$2.25

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$129.37M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
520.73K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.90
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.14 L
$7.2 H
$2.25

About Aldeyra The, Common Stock

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameALDXSectorS&P500
1-Week Return4.17%0.86%-1.29%
1-Month Return-3.02%-2.58%10.63%
3-Month Return-65.38%-10.87%-2.43%
6-Month Return-53.61%-8.73%-2.14%
1-Year Return-41.86%-10.19%10%
3-Year Return-20.49%0.5%46.86%
5-Year Return-47.31%32.08%97.3%
10-Year Return-68.44%75.49%174.39%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue56.22K264.18K258.71K262.78K249.62K[{"date":"2020-12-31","value":21.28,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.93,"profit":true},{"date":"2023-12-31","value":99.47,"profit":true},{"date":"2024-12-31","value":94.49,"profit":true}]
Gross Profit(56.22K)(264.18K)(258.71K)(262.78K)-[{"date":"2020-12-31","value":-5622100,"profit":false},{"date":"2021-12-31","value":-26418000,"profit":false},{"date":"2022-12-31","value":-25870700,"profit":false},{"date":"2023-12-31","value":-26278000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)-[{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses34.67M56.22M62.68M42.79M60.12M[{"date":"2020-12-31","value":55.31,"profit":true},{"date":"2021-12-31","value":89.69,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":68.27,"profit":true},{"date":"2024-12-31","value":95.91,"profit":true}]
Operating Income(36.42M)(56.22M)(62.68M)(42.79M)(60.12M)[{"date":"2020-12-31","value":-3642102000,"profit":false},{"date":"2021-12-31","value":-5621953600,"profit":false},{"date":"2022-12-31","value":-6267998700,"profit":false},{"date":"2023-12-31","value":-4279408300,"profit":false},{"date":"2024-12-31","value":-6011703200,"profit":false}]
Total Non-Operating Income/Expense(4.98M)(3.11M)1.31M9.95M8.53M[{"date":"2020-12-31","value":-50.02,"profit":false},{"date":"2021-12-31","value":-31.28,"profit":false},{"date":"2022-12-31","value":13.17,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":85.71,"profit":true}]
Pre-Tax Income(38.03M)(57.78M)(62.02M)(37.54M)(55.85M)[{"date":"2020-12-31","value":-3803299400,"profit":false},{"date":"2021-12-31","value":-5777627400,"profit":false},{"date":"2022-12-31","value":-6202463600,"profit":false},{"date":"2023-12-31","value":-3754251000,"profit":false},{"date":"2024-12-31","value":-5585144400,"profit":false}]
Income Taxes(479.26K)1.48M(655.35K)-(55.85T)[{"date":"2020-12-31","value":-32.43,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-44.34,"profit":false},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":-3779054766.8,"profit":false}]
Income After Taxes(37.55M)(59.25M)(61.37M)-55.85T[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income From Continuous Operations(37.55M)(57.78M)(62.02M)(45.69M)(55.85M)[{"date":"2020-12-31","value":-3755372900,"profit":false},{"date":"2021-12-31","value":-5777627400,"profit":false},{"date":"2022-12-31","value":-6202463600,"profit":false},{"date":"2023-12-31","value":-4569171000,"profit":false},{"date":"2024-12-31","value":-5585144400,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(37.55M)(59.25M)(61.37M)(37.54M)(55.85M)[{"date":"2020-12-31","value":-3755372900,"profit":false},{"date":"2021-12-31","value":-5925419500,"profit":false},{"date":"2022-12-31","value":-6136928500,"profit":false},{"date":"2023-12-31","value":-3754251000,"profit":false},{"date":"2024-12-31","value":-5585144400,"profit":false}]
EPS (Diluted)(1.12)(1.07)(1.06)(0.64)(0.94)[{"date":"2020-12-31","value":-112,"profit":false},{"date":"2021-12-31","value":-107,"profit":false},{"date":"2022-12-31","value":-106,"profit":false},{"date":"2023-12-31","value":-64,"profit":false},{"date":"2024-12-31","value":-94,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ALDX
Cash Ratio 6.30
Current Ratio 6.39

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ALDX
ROA (LTM) -32.60%
ROE (LTM) -65.19%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ALDX
Debt Ratio Lower is generally better. Negative is bad. 0.32
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.68

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ALDX
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.12
Price/FCF NM
EV/R 0.00
EV/Ebitda NM
PEG NM

FAQs

What is Aldeyra The share price today?

Aldeyra The (ALDX) share price today is $2.25

Can Indians buy Aldeyra The shares?

Yes, Indians can buy shares of Aldeyra The (ALDX) on Vested. To buy Aldeyra The from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ALDX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Aldeyra The be purchased?

Yes, you can purchase fractional shares of Aldeyra The (ALDX) via the Vested app. You can start investing in Aldeyra The (ALDX) with a minimum investment of $1.

How to invest in Aldeyra The shares from India?

You can invest in shares of Aldeyra The (ALDX) via Vested in three simple steps:

  • Click on Sign Up or Invest in ALDX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Aldeyra The shares
What is Aldeyra The 52-week high and low stock price?

The 52-week high price of Aldeyra The (ALDX) is $7.2. The 52-week low price of Aldeyra The (ALDX) is $1.14.

What is Aldeyra The price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Aldeyra The (ALDX) is 2.12

What is the Market Cap of Aldeyra The?

The market capitalization of Aldeyra The (ALDX) is $129.37M

What is Aldeyra The’s stock symbol?

The stock symbol (or ticker) of Aldeyra The is ALDX

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top